The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...